I don't consider the pancreatic trial a failure. I await the ASCO data with great interest. The trial allowed many later stage and older patients to take part. I expect earlier stage and younger patients did better.....so much better indeed that future trials will be based on the same earlier stage younger patients that other pancreatic trials have enrolled.
All immunotherapeutic approachs take time to work...and this is true of Bavi. I still see Bavi as part of a multi-drug cocktail that will be very effective against pancreatic cancer. We shall know more soon ....ASCO data is near.
But did it fail? And what does fail even mean in this context?
Yes, certainly the trial failed to hit stat sig on the OS primary. And if this was a P3 that would be enough to assign it an F.
But it was a P2, and these have many goals. One is to see enough signs of efficiacy to continue the program. With the OS trending well, and the secondaries hitting, I think it did well. Hitting stat sig for OS on a small P2 is very difficult.
Sometimes a P2 is looked at as an immediate lead in to a P3, but this is often not the case. The P2 might show the drug works, but looks like it should be combined with some other drugs.
Of course the devil is in the detail, but to me this trial was actually bavi's biggest success to date.
News 
Market Data 
Discover 
AI
